Should You Buy Canopy Growth Corp (TSX:WEED) Ahead of Earnings?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has struggled in recent months but a good quarter to start the new fiscal year could be just what the company needs to start a big rally.

| More on:
Businessman looking at a red arrow crashing through the floor

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is expected to release its latest quarterly results this week. It will be the company’s first quarter since a disastrous Q4 — and the first since the departure of former co-CEO Bruce Linton.

The start of a new fiscal year, this will be a big test for the cannabis giant to see whether it’s been able to make any progress in keeping its costs down and getting closer to profitability, which we know is a goal for the company.

However, given its rapid growth and many initiatives that Canopy Growth is working on, it would certainly be a big surprise for the stock to pull out a profit.

A none-too-impressive track record

For five straight quarters, Canopy Growth has fallen short of expectations. Before the release of Q4, the stock was trading around $57 and fell sharply afterwards.

Heading into this week, Canopy Growth was just over $43 and in danger of dropping below the $40 mark, which could certainly happen with another bad quarter.

While the company has been showing significant sales growth, the challenge has been further down the income statement, where Canopy Growth continues to see a lot of red.

Only once during the past 10 quarters have we seen the company record an operating profit, and that was two years ago. Over the trailing 12 months, Canopy Growth’s operating losses have totalled nearly $600 million.

Net income has been a bit more volatile, with other income and expenses causing a lot of noise on the company’s financials; they have helped Canopy Growth record a profit three times during the same period.

Odds are that we’ll see the continuation of that trend in Q1, the question simply being whether we see the problem getting worse or whether Canopy Growth is able to make some strides towards breakeven status.

Low price might make the stock a more attractive buy

One of the knocks on Canopy Growth in the past has been its extremely high valuation, which is sometimes hovering around the $20 billion mark.

With the recent declines, the stock is now closer to around $15 billion, and while that might still be high, it could give investors a lot more comfort in knowing that there probably isn’t as much of a risk of a big correction happening even if Canopy Growth falls short of expectations.

The last time the share price was below $40 was in early January, when it was recovering from a significant sell-off that took place in late 2018.

Is the stock worth the risk?

Although things have not been ideal for pot stocks lately, I’d be surprised if Canopy Growth didn’t find some support at $40. It could be a good price point to buy the stock at, especially now that we know management will be a bit more focused on expenses and getting the financials out of the red.

While this will take some time, over the long term, we could see some more improvements, as the company has already laid the groundwork for a lot of growth and can now focus on cost control.

For those bullish on the industry, the stock could be a relatively cheap buy as there looks to be a lot more upside than there is risk of the stock falling much lower than where it is today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »